Soluble interleukin-33 receptor (sST-2): a novel marker for assessing cardiovascular risk in rheumatoid arthritis

Authors:

Abstract
Background: Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, and it significantlyincreases the risk of cardiovascular disease and death. The evaluation of cardiovascular risk (CVR) is crucial inthese patients, but it may be underestimated using the current criteria, as they do not include nontraditionalCVR factors. Soluble ST-2, which is the circulating form of the IL-33 receptor, has been identified as a biomarkerfor cardiovascular and rheumatic diseases. In this study, we examined the role of sST-2 in assessing CVR in RA.Methods: Monocentric, retrospective, observational trial. Inclusion of RA patients on variable DMARD therapy.Analysis of RA disease using established scores (DAS 28, VAS, HFQ), clinical findings (number of swollen and painfuljoints), and laboratory investigation. Documentation of numerous CVR variables. Quantification of solublesST-2 by ELISA.Results: In total, 129 individuals were included. Soluble sST-2 did neither correlate nor was associated with anyvariable of RA disease activity. In contrast, significant associations were identified between sST-2 and a numberof established CVR markers.Conclusions: The data indicates a novel role for sST-2 in CVR prediction in RA.

This publication has 34 references indexed in Scilit: